[go: up one dir, main page]

WO2006014359A3 - Composes utiles pour inhiber la chk1 - Google Patents

Composes utiles pour inhiber la chk1 Download PDF

Info

Publication number
WO2006014359A3
WO2006014359A3 PCT/US2005/023554 US2005023554W WO2006014359A3 WO 2006014359 A3 WO2006014359 A3 WO 2006014359A3 US 2005023554 W US2005023554 W US 2005023554W WO 2006014359 A3 WO2006014359 A3 WO 2006014359A3
Authority
WO
WIPO (PCT)
Prior art keywords
heteroaryl
group
compounds useful
3alkylenec
6alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/023554
Other languages
English (en)
Other versions
WO2006014359A2 (fr
Inventor
John Joseph Gaudino
Adam Wade Cook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icos Corp
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Priority to CA002573063A priority Critical patent/CA2573063A1/fr
Priority to US11/630,626 priority patent/US7560462B2/en
Priority to EP05791683A priority patent/EP1768977A2/fr
Priority to JP2007519487A priority patent/JP2008505112A/ja
Priority to BRPI0512891-9A priority patent/BRPI0512891A/pt
Priority to MX2007000265A priority patent/MX2007000265A/es
Priority to AU2005270102A priority patent/AU2005270102A1/en
Publication of WO2006014359A2 publication Critical patent/WO2006014359A2/fr
Anticipated expiration legal-status Critical
Publication of WO2006014359A3 publication Critical patent/WO2006014359A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés d'urée à substitution, utiles dans le traitement de maladies et d'états pathologiques associés à des dommages à l'ADN ou des lésions de l'ADN lors de la réplication de l'ADN. Cette invention concerne également des procédés pour produire lesdits composés et leur utilisation comme agents thérapeutiques, par exemple, dans le traitement du cancer ou d'autres maladies caractérisées par des défauts apparaissant lors de la réplication de l'ADN, la ségrégation des chromosomes ou la division cellulaire.
PCT/US2005/023554 2004-07-02 2005-07-01 Composes utiles pour inhiber la chk1 Ceased WO2006014359A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002573063A CA2573063A1 (fr) 2004-07-02 2005-07-01 Composes utiles pour inhiber la chk1
US11/630,626 US7560462B2 (en) 2004-07-02 2005-07-01 Compounds useful for inhibiting CHK1
EP05791683A EP1768977A2 (fr) 2004-07-02 2005-07-01 Composes utiles pour inhiber la chk1
JP2007519487A JP2008505112A (ja) 2004-07-02 2005-07-01 Ｃｈｋ１の阻害に有用な化合物
BRPI0512891-9A BRPI0512891A (pt) 2004-07-02 2005-07-01 composto e um sal ou pró-droga ou solvato farmaceuticamente aceitável do mesmo, composição, métodos de inibir a quinase 1 do ponto de verificação em uma célula, de sensibilizar células em um indivìduo que passa por um tratamento quimioterapêutico ou radioterapêutico para uma condição médica e de inibir a proliferação de célula aberrante, uso de um composto, e artigo de fabricação para o uso farmacêutico em humano
MX2007000265A MX2007000265A (es) 2004-07-02 2005-07-01 Compuestos utiles para inhibir chk1.
AU2005270102A AU2005270102A1 (en) 2004-07-02 2005-07-01 Compounds useful for inhibiting Chk1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58529204P 2004-07-02 2004-07-02
US60/585,292 2004-07-02

Publications (2)

Publication Number Publication Date
WO2006014359A2 WO2006014359A2 (fr) 2006-02-09
WO2006014359A3 true WO2006014359A3 (fr) 2007-01-11

Family

ID=35515699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/023554 Ceased WO2006014359A2 (fr) 2004-07-02 2005-07-01 Composes utiles pour inhiber la chk1

Country Status (10)

Country Link
US (1) US7560462B2 (fr)
EP (1) EP1768977A2 (fr)
JP (1) JP2008505112A (fr)
KR (1) KR20070043996A (fr)
CN (1) CN101010316A (fr)
AU (1) AU2005270102A1 (fr)
BR (1) BRPI0512891A (fr)
CA (1) CA2573063A1 (fr)
MX (1) MX2007000265A (fr)
WO (1) WO2006014359A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662910B2 (en) 2004-10-20 2010-02-16 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US8455652B2 (en) 2003-04-03 2013-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitors for the soluble epoxide hydrolase
US8501783B2 (en) 2006-03-13 2013-08-06 The Regents Of The University Of California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
US8513302B2 (en) 2003-04-03 2013-08-20 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
US9296693B2 (en) 2010-01-29 2016-03-29 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778648A2 (fr) * 2004-08-19 2007-05-02 ICOS Corporation Composes utiles pour inhiber chk1
EP2066642A1 (fr) * 2006-09-25 2009-06-10 Arete Therapeutics, INC. Inhibiteurs d'époxyde hydrolase soluble
EP2200431B1 (fr) * 2007-09-10 2016-07-20 Boston Biomedical, Inc. Compositions et procédés nouveaux pour le traitement du cancer
EP2070929A1 (fr) * 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Composés d'alkynylaryle et sels correspondants, compositions pharmaceutiques contenant ceux-ci, procédés de préparation de ceux-ci et usage de ceux-ci
GB201008005D0 (en) * 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
GB201119799D0 (en) 2011-11-16 2011-12-28 Sentinel Oncology Ltd Pharmaceutical compounds
SG10201801205YA (en) 2013-04-09 2018-04-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
HUE046008T2 (hu) * 2014-07-17 2020-02-28 Sunshine Lake Pharma Co Ltd I-(5-terc-butil)-izoxazol-3-il)-3-(4-((feniI)-etinil)-fenil)-kabamid származékok, valamint az ezekkel rokon vegyületek FLT-3 inhibitorokként rák kezelésére
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
CN107922375B (zh) * 2015-07-30 2020-05-22 正大天晴药业集团股份有限公司 靶向idh2突变的抗肿瘤化合物及其使用方法
SI3411036T1 (sl) 2016-02-04 2022-03-31 Pharmaengine, Inc. 3,5-disubstituirani pirazoli, uporabni kot kontrolne točke inhibitorjev kinaze 1 (CHK1), ter njihovi pripravki in uporaba
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018183891A1 (fr) 2017-03-31 2018-10-04 Cascadian Therapeutics Combinaisons d'inhibiteurs de chk1 et wee1
CA3062656A1 (fr) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methodes pour le traitement du cancer
WO2021119236A1 (fr) 2019-12-10 2021-06-17 Seagen Inc. Préparation d'un composé inhibiteur de chk1
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
GB202107932D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01163723A (ja) * 1987-12-21 1989-06-28 Nippon Telegr & Teleph Corp <Ntt> 有機非線形光学材料
WO2002070494A1 (fr) * 2001-03-02 2002-09-12 Icos Corporation Uree aryle et heteroaryle utilisee en tant qu'inhibiteur de chk1, a utiliser en tant que radiosensibilisants et chimiosensibilisants
WO2003051366A2 (fr) * 2001-12-13 2003-06-26 Abbott Laboratories Inhibiteurs de kinase
WO2004014876A1 (fr) * 2002-08-13 2004-02-19 Abbott Laboratories Derives d'uree comme inhibiteurs de kinase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL195808B1 (pl) * 1997-12-22 2007-10-31 Bayer Corp Moczniki arylowe, kompozycja je zawierająca i ichzastosowanie
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01163723A (ja) * 1987-12-21 1989-06-28 Nippon Telegr & Teleph Corp <Ntt> 有機非線形光学材料
WO2002070494A1 (fr) * 2001-03-02 2002-09-12 Icos Corporation Uree aryle et heteroaryle utilisee en tant qu'inhibiteur de chk1, a utiliser en tant que radiosensibilisants et chimiosensibilisants
WO2003051366A2 (fr) * 2001-12-13 2003-06-26 Abbott Laboratories Inhibiteurs de kinase
WO2004014876A1 (fr) * 2002-08-13 2004-02-19 Abbott Laboratories Derives d'uree comme inhibiteurs de kinase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KURIHARA, TAKASHI ET AL: "Organic nonlinear optical material with high third harmonic generation", XP002363142, retrieved from STN Database accession no. 1990:45304 *
LU, XIAOLING ET AL: "Thermolysis of Benzannulated Enyne-Carbodiimides. Application in the Synthesis of Pyrido[1',2':1,2]pyrimido[4,5-b]indoles and Related Heteroaromatic Compounds", JOURNAL OF ORGANIC CHEMISTRY , 67(22), 7797-7801 CODEN: JOCEAH; ISSN: 0022-3263, 2002, XP002363139 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455652B2 (en) 2003-04-03 2013-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitors for the soluble epoxide hydrolase
US8513302B2 (en) 2003-04-03 2013-08-20 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
US7662910B2 (en) 2004-10-20 2010-02-16 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US8476043B2 (en) 2004-10-20 2013-07-02 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US8501783B2 (en) 2006-03-13 2013-08-06 The Regents Of The University Of California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
US9029550B2 (en) 2006-03-13 2015-05-12 The Regents Of The University Of California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
US9296693B2 (en) 2010-01-29 2016-03-29 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase

Also Published As

Publication number Publication date
CN101010316A (zh) 2007-08-01
CA2573063A1 (fr) 2006-02-09
US20080214573A1 (en) 2008-09-04
MX2007000265A (es) 2007-07-20
EP1768977A2 (fr) 2007-04-04
KR20070043996A (ko) 2007-04-26
AU2005270102A1 (en) 2006-02-09
BRPI0512891A (pt) 2008-04-15
WO2006014359A2 (fr) 2006-02-09
JP2008505112A (ja) 2008-02-21
US7560462B2 (en) 2009-07-14

Similar Documents

Publication Publication Date Title
WO2006014359A3 (fr) Composes utiles pour inhiber la chk1
AU2015231234B2 (en) Antifungal compound process
WO2000075144A2 (fr) Catalyseurs de decomposition du peroxynitrite et methodes d&#39;utilisation desdits catalyseurs
EP1301515B1 (fr) Metalloporphyrines non genotoxiques comme scavengers catalytiques synthetiques d&#39;especes d&#39;oxygene reactif
KR102603277B1 (ko) 항진균성 화합물 및 이의 제조 방법
YU69003A (sh) Aril i heteroaril urea chk1 inhibitori kao jedinjenja koja povećavaju osetljivost na radioterapiju i hemoterapiju
EP3166938A2 (fr) Échafaudages 2-imidazolyl-pyrimidine en tant qu&#39;inhibiteurs puissants et sélectifs de l&#39;oxyde nitrique synthase neuronale
NO20080871L (no) N-(Heteroaryl)-1-heteroarylalkyl-1 H-indol-2-karboksamidderivater, fremstilling og terapeutisk anvendelse derav
Umezawa et al. Facile synthesis of peptide–porphyrin conjugates: towards artificial catalase
BRPI0507984A (pt) composto ou um sal do mesmo, processo para produzir um composto, medicamento, métodos para antagonizar angiotensina ii em um mamìfero, para melhorar a resistência de insulina em um mamìfero e para prevenir ou tratar doenças circulatórias em um mamìfero, e, uso do composto
WO2008106080A3 (fr) Synthèse de désacétoxytubulysine h et ses analogues
RU2007105350A (ru) 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы
US8334377B2 (en) Porphyrin catalysts and methods of use thereof
KR20160138012A (ko) 항진균 화합물 제조방법
EP2366691B1 (fr) Nitropyridinyléthylèneimine, composition pharmaceutique l&#39;incluant, sa méthode de synthèse et ses applications
US20150152390A1 (en) Compounds With Modifying Activity Enhanced Under Hypoxic Conditions
WO2012139043A2 (fr) Inhibiteurs sélectifs de l&#39;oxyde nitrique synthase neuronal
JP4707393B2 (ja) 抗癌化合物
EP2066680B1 (fr) Donneurs d&#39;oxyde nitrique de type thionitrite de triphénylphosphonium
MX2007012116A (es) Derivados de heteroaril urea utiles para inhibir chk1.
AU2021392700B2 (en) Novel n-heterocyclic bet bromodomain inhibitor, and preparation method therefor and medical use thereof
MY139586A (en) Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives for reducing ichaemic damage
Lin et al. Crystal structure and superoxide dismutase activity of a six-coordinate manganese (III) complex
EP3551634A1 (fr) Pyrazoloazépin-8-ones substituées, et leur utilisation en tant qu&#39;inhibiteurs de la phosphodiestérase
EP1904060B1 (fr) Utilisation de derives de phtalocyanine pour le traitement non photodynamique de maladies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007519487

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2573063

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/000265

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2005791683

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005270102

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077002555

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 468/CHENP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005270102

Country of ref document: AU

Date of ref document: 20050701

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005270102

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580029406.1

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005791683

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11630626

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0512891

Country of ref document: BR